Adam Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD, is professor of medicine at the University of Pittsburgh School of Medicine and serves as the associate director of clinical investigation for the University of Pittsburgh Cancer Institute. He is board certified in internal medicine and medical oncology by the American Board of Internal Medicine, and is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research.
Dr. Brufsky received both his medical degree and doctorate from the University of Connecticut School of Medicine. He completed his residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School and a fellowship in medical oncology and bone marrow transplantation at the Dana-Farber Cancer Institute. Prior to joining the University of Pittsburgh, Dr. Brufsky served as an associate physician and instructor in medicine at Harvard Medical School.
In addition to his other professional responsibilities, Dr. Brufsky is currently the principal investigator of the Pittsburgh Breast Cancer Consortium, a program intended to increase community access to innovative clinical trials for the treatment of metastatic breast cancer, as well as a number of other breast cancer studies.
- FDA Approves Bone Medicine for Use in Bone Metastasis
- Bone Mets
- Metastatic Triple-Negative Breast Cancer
- Perspectives on Metastatic Breast Cancer
- Good Dental Hygiene May Help Prevent Osteonecrosis
- January 2013 Ask the Expert: Making Treatment Decisions for the Newly Diagnosed
- Study Supports Use of Zoledronic Acid for Early Breast Cancer
- January 2013 Ask the Expert: ATLAS Study on Tamoxifen
- Bone Health
- Trial Compares HER2-positive Therapies in People With Early Breast Cancer
- Phase II Study Shows New Medicine May Slow Metastatic Breast Cancer
- Research May Mean Fewer Side Effects For Women With Bone Metastases
- Zoledronic Acid May Prevent Cancer Return in Postmenopausal Women With Early-Stage Breast Cancer